These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38706351)

  • 1. Structural Insights of PD-1/PD-L1 Axis: An
    Rohit S; Patel M; Jagtap Y; Shah U; Patel A; Patel S; Solanki N
    Curr Protein Pept Sci; 2024; 25(8):638-650. PubMed ID: 38706351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.
    Shi D; Zhou S; Liu X; Zhao C; Liu H; Yao X
    Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):576-588. PubMed ID: 29203283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method.
    Lim H; Chun J; Jin X; Kim J; Yoon J; No KT
    Sci Rep; 2019 Nov; 9(1):16727. PubMed ID: 31723178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab.
    Roither B; Oostenbrink C; Schreiner W
    BMC Bioinformatics; 2020 Dec; 21(Suppl 17):557. PubMed ID: 33308148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and interactions of the human programmed cell death 1 receptor.
    Cheng X; Veverka V; Radhakrishnan A; Waters LC; Muskett FW; Morgan SH; Huo J; Yu C; Evans EJ; Leslie AJ; Griffiths M; Stubberfield C; Griffin R; Henry AJ; Jansson A; Ladbury JE; Ikemizu S; Carr MD; Davis SJ
    J Biol Chem; 2013 Apr; 288(17):11771-85. PubMed ID: 23417675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of pH-dependent interactions between PD-1 and PD-L1 immune checkpoint proteins from molecular dynamics.
    Klyukin K; Alexandrov V
    Proteins; 2020 Sep; 88(9):1162-1168. PubMed ID: 32105362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular dynamics simulations elucidate conformational selection and induced fit mechanisms in the binding of PD-1 and PD-L1.
    Liu W; Huang B; Kuang Y; Liu G
    Mol Biosyst; 2017 May; 13(5):892-900. PubMed ID: 28327740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors.
    Almahmoud S; Zhong HA
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31546905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
    Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
    Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations.
    Sun X; Yan X; Zhuo W; Gu J; Zuo K; Liu W; Liang L; Gan Y; He G; Wan H; Gou X; Shi H; Hu J
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29986511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.
    Zak KM; Kitel R; Przetocka S; Golik P; Guzik K; Musielak B; Dömling A; Dubin G; Holak TA
    Structure; 2015 Dec; 23(12):2341-2348. PubMed ID: 26602187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction.
    Kawashita S; Aoyagi K; Yamanaka H; Hantani R; Naruoka S; Tanimoto A; Hori Y; Toyonaga Y; Fukushima K; Miyazaki S; Hantani Y
    Bioorg Med Chem Lett; 2019 Sep; 29(17):2464-2467. PubMed ID: 31351692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD).
    Du J; Qin Y; Wu Y; Zhao W; Zhai W; Qi Y; Wang C; Gao Y
    Cell Commun Signal; 2018 Jun; 16(1):25. PubMed ID: 29879980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A computational study of co-inhibitory immune complex assembly at the interface between T cells and antigen presenting cells.
    Su Z; Dhusia K; Wu Y
    PLoS Comput Biol; 2021 Mar; 17(3):e1008825. PubMed ID: 33684103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based derivation and intramolecular cyclization of peptide inhibitors from PD-1/PD-L1 complex interface as immune checkpoint blockade for breast cancer immunotherapy.
    Zhou K; Lu J; Yin X; Xu H; Li L; Ma B
    Biophys Chem; 2019 Oct; 253():106213. PubMed ID: 31276987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in silico investigation on the binding site preference of PD-1 and PD-L1 for designing antibodies for targeted cancer therapy.
    Abdolmaleki S; Ganjalikhani Hakemi M; Ganjalikhany MR
    PLoS One; 2024; 19(7):e0304270. PubMed ID: 39052609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein-Protein Interaction.
    Klimek J; Kruc O; Ceklarz J; Kamińska B; Musielak B; van der Straat R; Dӧmling A; Holak TA; Muszak D; Kalinowska-Tłuścik J; Skalniak Ł; Surmiak E
    Molecules; 2024 Jun; 29(11):. PubMed ID: 38893521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kaempferol and Its Glycoside, Kaempferol 7-O-Rhamnoside, Inhibit PD-1/PD-L1 Interaction In Vitro.
    Kim JH; Kim YS; Choi JG; Li W; Lee EJ; Park JW; Song J; Chung HS
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32375257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach.
    Paciotti R; Agamennone M; Coletti C; Storchi L
    J Comput Aided Mol Des; 2020 Aug; 34(8):897-914. PubMed ID: 32185582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
    Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
    Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.